Skip to main content

Serum sialic acid in malignant tumors, bacterial infections, and chronic liver diseases

Journal of Cancer Research and Clinical Oncology volume 109, pages 55–59 (1985)Cite this article

Summary

The total serum sialic acid concentration was determined in 2,264 persons with various malignant tumors, bacterial infections, rheumatic diseases, and chronic liver diseases, and in a control group. The thiobarbiturate method according to Warren was used [34].

The upper limit (95% percentile) in the control group was 2.23 μmol/ml. Higher values were found in the groups with neoplasms (mean: 3.04 μmol/ml), inflammatory diseases (e.g., pneumonia: 3.02 μmol/ml), and active rheumatoid arthritis (3.05 μmol/ml). In the group with malignant diseases, the sialic acid concentration at the time of diagnosis was highest for bronchial carcinoma (3.29 μmol/ml) and lowest for breast cancer (2.58 μmol/ml). In chronic liver diseases the mean sialic acid level was lower than in a heterogeneous group of noninflammatory and nonneoplastic diseases.

The estimation of the serum sialic acid concentration could be useful in the detection of tumor burden and metastases, and in the evaluation of the later course and prognosis of malignant neoplasms if bacterial/inflammatory and active rheumatoid processes can be excluded.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Beck WP van, Smets LA, Emmelot P (1965) Increased sialic acid density in surface glycoproteins of transformed and malignant cells: A general phenomenon? Cancer 18:1285–1291

    PubMed  Google Scholar 

  2. Bosman HB, Hall TC (1974) Enzyme activity in invasive tumors of human breast and colon. Proc Natl Acad Sci USA 71:1833–1837

    PubMed  Google Scholar 

  3. Böttiger LE, Carlson LA (1969) Serum glycoprotein concentrations in normal men. Cin Chim Acta 5:664–671

    Google Scholar 

  4. Böttiger LE, Norberg R (1964) Studies in sarcoidosis. II. Serum protein carbohydrates. Acta Med Scand 175:373–381

    PubMed  Google Scholar 

  5. Brozmanova E, Skrovins B (1972) Sialic acid and bone tumors. Neoplasma 19:115–124

    Google Scholar 

  6. Cabezas JA; Va'zquez-Porto R, Vázquez-Pernas R, Pena J (1962) Tenues en acidN-acétylneuraminique de sérums sanguins humains. Clin Chim Acta 7:406–415

    PubMed  Google Scholar 

  7. Carter A, Martin NH (1962) Serum sialic acid levels in health and disease. J Clin Pathol 15:69–72

    PubMed  Google Scholar 

  8. Dixon WJ (ed) (1981) BMDP statistical software. University of California Press, Berkeley

    Google Scholar 

  9. Ganzinger U, Dorner F, Unger FM, Moser K, Jentzsch K (1977) Erhöhung der Serum-Sialyltransferase bei menschlichen Malignomen: Grundlage für ein neues Diagnosticum? Klin Wochenschr 55:553–555

    PubMed  Google Scholar 

  10. Greenspan EM, Tepper B, Terry LL, Schoenbach EB (1952) The serum mucoproteins as an aid in the differentiation of neoplastic from primary parenchymatous liver disease. J Lab Clin Med 39:44–56

    PubMed  Google Scholar 

  11. Hogan-Ryan A, Fennelly JJ, Jones M, Cantwell B, Buffy MJ (1980) Serum sialic acid and CEA concentrations in human breast cancer. Br J Cancer 41:587–592

    PubMed  Google Scholar 

  12. Holm S (1979) A simple sequential rejection multiple test procedure. Scand J Stat 6:65–70

    Google Scholar 

  13. Horgan IE (1982) Total and lipid-bound sialic acid levels in sera from patients with cancer. Clin Chim Acta 118:327–331

    PubMed  Google Scholar 

  14. Jakab L, Féher J (1973) Serum glycoproteids in connective-tissue diseases and other pathologic conditions. Acta Med Acad Sci Hung 30:219–225

    PubMed  Google Scholar 

  15. Kafka V, Musil J (1977) The use of serial determination of blood serum glycoproteins for indirect evidence of the sensitivity and resistance of malignant tumor cells to clinical chemotherapy. Neoplasma 24:101–107

    PubMed  Google Scholar 

  16. Katapodis N, Hirshaut Y, Geller NL, Stock CC (1982) Lipid-associated sialic acid test for the detection of human cancer. Cancer Res 42:5270–5275

    PubMed  Google Scholar 

  17. Kessel D, Allen J (1975) Elevated plasma sialyltransferase in the cancer patient. Cancer Res 35:670–672

    Google Scholar 

  18. Khadapkar SV, Sheth NA, Bhide SV (1975) Independence of sialic acid levels in normal and malignant growth. Cancer Res. 35:1520–1523

    PubMed  Google Scholar 

  19. Kiricuta O, Bojan O, Comes R, Christian R (1979) Significance of serum fucose, sialic acid, haptaglobin and phospholipids levels in the evolution and treatment of breast cancer. Arch Geschwulstforsch 49:106–112

    PubMed  Google Scholar 

  20. Krolikowski FJ, Renter K, Waalkes TP, Sieber SM, Adamson RH (1976) Serum sialic acid levels in lung cancer patients. Pharmacology 14:47–51

    PubMed  Google Scholar 

  21. Kunstmann FW (1980) Die fraktionierte Bestimmung derN-Azetylneuraminsäure. Deutsche Gesundheitswesen 35:1685–1688

    Google Scholar 

  22. Mabry EW, Carubelli R (1972) Sialic acid in human cancer. Experientia 28:182–183

    Google Scholar 

  23. MacBeth RAL, Bekesi JG (1962) Plasma glycoproteins in various disease states including carcinoma. Cancer Res 22:1170–1176

    Google Scholar 

  24. McNeil C, Berrett CR, Su LY, Trentelman EF, Helmick Wm (1965) Sialic acid as a measure of serum glycoproteins. Am J Clin Pathol 43:130–133

    PubMed  Google Scholar 

  25. Moss AJ, Bissada NK, Boyd CM, Hunter WC (1979) Significance of protein-bound neuraminic acid levels in patients with prostatic and bladder carcinoma. Urology 13:182–184

    PubMed  Google Scholar 

  26. Mrochek JE, Dinsmore SR, Tormey DC, Waalkes TP (1976) Protein-bound carbohydrates in breast cancer. Liquid chromatographic analysis for mannose, galactose, fucose and sialic acid in serum. Clin Chem 22:1516–1521

    PubMed  Google Scholar 

  27. Nicolson GL, Poste G (1976) The cancer cell: Dynamic aspects and modifications in cell-surface organization. II. N Engl J Med 295:253–258

    PubMed  Google Scholar 

  28. Ruhenstroht-Bauer G, Fuhrmann GF, Kübler W, Rueff F, Munk K (1962) Zur Bedeutung der Neuraminsäuren in der Zellmembran für das Wachstum maligner Zellen. Z Krebsforsch 65:37–43

    PubMed  Google Scholar 

  29. Shetlar MR, Foster JV, Kelly KH, Shetlar CL, Bryan RS, Everett MR (1949) The serum polysaccharide level in malignancy and in other pathological conditions. Cancer Res 9:515–519

    Google Scholar 

  30. Silver HKB, Rangel DM, Morton DL (1978) Serum sialic acid elevations in malignant melanoma patients. Cancer 41:1497–1499

    PubMed  Google Scholar 

  31. Silver HKB, Karim KA, Salinas FA, Swenerton KD (1981) Significance of sialic acid and carcinoembryonic antigen as monitors of tumor burden among patients with carcinoma of the ovary. Surg Gynecol Obstet 153:209–213

    PubMed  Google Scholar 

  32. Silver HKB, Murray RN, Worth AJ, Salinas FA, Spinelli JJ (1983) Prediction of malignant melanoma recurrence by serumN-acetylneuraminic acid. Int J Cancer 31:39–43

    PubMed  Google Scholar 

  33. Tuppy H, Gottschalk A (1972) In: Gottschalk A (ed) Glycoproteins. Their composition, structure and function, 2nd edn. Amsterdam, pp 403–449

  34. Warren L (1959) The thiobarbituric acid assay of sialic acids. J Biol Chem 234:1971–1975

    PubMed  Google Scholar 

  35. Warren L, Fuhrer JP, Buck CA (1972) Surface glycoproteins of normal and transformed cells: A difference determined by sialic acid and growth-dependent sialyl transferase. Proc Natl Acad Sci USA 69:1838–1842

    PubMed  Google Scholar 

  36. Weiss L (1973) Neuraminidase, sialic acids and cells interactions. J Natl Cancer Inst 50:3–19

    PubMed  Google Scholar 

  37. Welch PL (1938) Significance of the difference between two means when the population variance is unequal. Biometrika 29:350–362

    Google Scholar 

  38. Winzler RJ, Smyth IM (1948) Studies on the mucoproteins of human plasme. II. Plasma mucoprotein levels in cancer patients. J Clin Invest 27:616–619

    Google Scholar 

Download references

Author information

Affiliations

  1. Interne Abteilung des Allgemeinen öffentlichen Krankenhauses Krems und Institut für medizinische Alkoholstudien, Wien, Österreich

    N. Stefenelli & H. Klotz

  2. Orthopädische Universitätsklinik, Wien, Österreich

    A. Engel

  3. Institut für medizinische Statistik und Dokumentation der Universität Wien, Wien, Österreich

    P. Bauer

Authors
  1. N. Stefenelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Engel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Stefenelli, N., Klotz, H., Engel, A. et al. Serum sialic acid in malignant tumors, bacterial infections, and chronic liver diseases. J Cancer Res Clin Oncol 109, 55–59 (1985). https://doi.org/10.1007/BF01884255

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01884255

Key words

  • Serum salic acid
  • Malignant tumors
  • Liver diseases